Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curatis Holding AGXSWX:CURN +6.84%30 Days Sales Outstanding is 46.14 as of Dec. 2025, which is 29% below its 10-year median of 65.12. GuruFocus rates XSWX:CURN with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 946 Drug Manufacturers companies, Curatis Holding AG ranks better than 75.48% on this metric.
The historical rank and industry rank for Curatis Holding AG's Days Sales Outstanding or its related term are showing as below:
XSWX:CURN'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.77 Med: 65.12 Max: 80.4
Current: 48.77
During the past 5 years, Curatis Holding AG's highest Days Sales Outstanding was 80.40. The lowest was 48.77. And the median was 65.12.
XSWX:CURN's Days Sales Outstanding is ranked better than 75.48% of 946
companies
in the Drug Manufacturers industry
Industry Median: 71.885
vs XSWX:CURN: 48.77
Curatis Holding AG's Days Sales Outstanding
declined
from Dec. 2024 (49.01) to Dec. 2025 (46.14).
Curatis Holding AG (XSWX:CURN) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Curatis Holding AG Days Sales Outstanding Related Terms
Curatis Holding AG Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Curatis Holding AG's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:CURN vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curatis Holding AG Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Curatis Holding AG's Days Sales Outstanding falls into.
Curatis Holding AG Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curatis Holding AG (XSWX:CURN) has a Days Sales Outstanding of 46.14 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Curatis Holding AG and its competitors. This is 29% below median its historical median of 65.12. Over the past decade, Curatis Holding AG's Days Sales Outstanding has ranged from 48.77 to 80.40. According to the industry distribution chart, Curatis Holding AG ranks #232 out of 946 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is Curatis Holding AG's Days Sales Outstanding too high?
Curatis Holding AG's current Days Sales Outstanding of 46.14 is 29% below median its 10-year median of 65.12. Over the past 10 years, this metric has ranged from a low of 48.77 to a high of 80.40. The Drug Manufacturers industry median Days Sales Outstanding is 71.89. Curatis Holding AG's value of 46.14 is 35.8% below this industry median. Based on the distribution chart, Curatis Holding AG ranks #232 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curatis Holding AG has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curatis Holding AG ranks #232 out of 946 companies for Days Sales Outstanding. This places Curatis Holding AG in the top 25% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 71.89. Curatis Holding AG's value of 46.14 is 35.8% below this benchmark. Historically, Curatis Holding AG's own Days Sales Outstanding has ranged from 48.77 to 80.40 over the past decade. While the company's 10-year median is 65.12 vs. the industry median of 71.89, Curatis Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.89, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curatis Holding AG's current Days Sales Outstanding of 46.14 is 35.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Curatis Holding AG and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curatis Holding AG's current Days Sales Outstanding is 46.14, which is 29% below median its own 10-year median of 65.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current Days Sales Outstanding of 46.14. The current Days Sales Outstanding is 46.14, which is 29% below median its 10-year median of 65.12 and 35.8% below the Drug Manufacturers industry median of 71.89. Curatis Holding AG's overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current Days Sales Outstanding is 46.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
30GF Score
Get the complete analysis for XSWX:CURN
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CURN has been successfully added to your 
